Cancer gene therapy
mTORC1/2 inhibition induces tumor regression in CDK4/6 inhibitor-insensitive acral melanoma.
Jeremy A Bravo Narula, Kasturee Jagirdar, Sumaiya Begum, Kuai Yu, Meihan Wei, Bailey Roberson, Marie Portuallo, Limin An, Steffanus Hallis, Viviana A Smart, Manoel O Moraes Junior, Qin Liu, Hongkai Ji, Vito W Rebecca
Published: 202510.1038/s41417-025-00987-5
Abstract
Acral melanoma (AM), a rare and aggressive subtype with 5-year survival rates below 16%, exhibits limited response to CDK4/6 inhibitors (CDK4i/6i) despite frequent pathway alterations. Here, we identify AKT-mTOR signaling as a critical escape mechani…
Preview only. Read the full abstract at the source